The predictive value of transaminases at admission in patients hospitalized for heart failure: findings from the RO-AHFS registry

被引:25
作者
Ambrosy, Andrew P. [1 ]
Gheorghiade, Mihai [2 ]
Bubenek, Serban [3 ]
Vinereanu, Dragos [4 ]
Vaduganathan, Muthiah [5 ]
Macarie, Cezar [3 ]
Chioncel, Ovidiu [3 ]
机构
[1] Stanford Univ, Sch Med, Stanford, CA USA
[2] Northwestern Univ Feinberg Sch Med, Chicago, IL USA
[3] Inst Emergency Cardiovasc Dis CC Iliescu Cardiol, Bucharest, Romania
[4] Univ Emergency Hosp, Bucharest, Romania
[5] Massachusetts Gen Hosp, Boston, MA USA
关键词
Alanine transaminase; aspartate transaminase; hospitalization; mortality;
D O I
10.1177/2048872612474906
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Background: Transaminases are commonly elevated in both the inpatient and ambulatory settings in heart failure (HF). Aims: To determine the prevalence and degree of elevated transaminase levels at admission and to evaluate the association between transaminase levels and in-hospital morbidity and mortality. Methods: Over a 12-month period, the Romanian Acute Heart Failure Syndromes (RO-AHFS) registry enrolled consecutive patients hospitalized for HF at 13 medical centres. A post-hoc analysis of the 489 patients (15.2%) with alanine transaminase (ALT) and aspartate transaminase (AST) (upper limits of normal 31 IU/l and 32 IU/l, respectively) measured at baseline was performed. In-hospital mortality was compared across quartiles using multivariable Cox regression models. Results: The prevalences of elevated ALT and AST were 28% and 24% and the medians (interquartile range) were 22 (16-47) and 23 (16-37 IU/L). Patients with elevated transaminases more commonly had right HF, cardiogenic shock, or an ejection fraction <45%. Patients with an ALT in the highest quartile were more likely to present with hypotension and a low pulse pressure, to have electrocardiographic evidence of left ventricular dyssynchrony and echocardiographic findings including increased left ventricular dimensions, reduced left ventricular ejection fraction, and valvular heart disease, to require inotropic or vasopressor support during hospitalization, and to report lower beta-blocker and angiotensin-converting enzyme inhibitor utilization. After adjusting for potential confounders, ALT was directly associated with BUN increases >= 10 mg/dl, necessity for intensive care unit admission, and longer length of stay. Patients in the highest quartile of ALT experienced significantly higher rates of all-cause mortality. Conclusions: In patients hospitalized for HF, there is a graded relationship between admission transaminase levels and surrogates for in-hospital morbidity, while more pronounced elevations of ALT predict in-hospital mortality independent of known prognostic indicators.
引用
收藏
页码:99 / 108
页数:10
相关论文
共 25 条
[1]
In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications - An analysis from the Acute Decompensated Heart Failure National Registry (ADHERE) [J].
Abraham, WT ;
Adams, KF ;
Fonarow, GC ;
Costanzo, MR ;
Berkowitz, RL ;
LeJemtel, TH ;
Cheng, ML ;
Wynne, J .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (01) :57-64
[2]
Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program [J].
Allen, Larry A. ;
Felker, G. Michael ;
Pocock, Stuart ;
McMurray, John J. V. ;
Pfeffer, Marc A. ;
Swedberg, Karl ;
Wang, Duolao ;
Yusuf, Salim ;
Michelson, Eric L. ;
Granger, Christopher B. .
EUROPEAN JOURNAL OF HEART FAILURE, 2009, 11 (02) :170-177
[3]
Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial [J].
Ambrosy, Andrew P. ;
Vaduganathan, Muthiah ;
Huffman, Mark D. ;
Khan, Sadiya ;
Kwasny, Mary J. ;
Fought, Angela J. ;
Maggioni, Aldo P. ;
Swedberg, Karl ;
Konstam, Marvin A. ;
Zannad, Faiez ;
Gheorghiade, Mihai .
EUROPEAN JOURNAL OF HEART FAILURE, 2012, 14 (03) :302-311
[4]
The importance of abnormalities of liver function tests in predicting mortality in chronic heart failure [J].
Batin, P ;
Wickens, M ;
McEntegart, D ;
Fullwood, L ;
Cowley, AJ .
EUROPEAN HEART JOURNAL, 1995, 16 (11) :1613-1618
[5]
The Romanian Acute Heart Failure Syndromes (RO-AHFS) Registry [J].
Chioncel, Ovidiu ;
Vinereanu, Dragos ;
Datcu, Mihai ;
Ionescu, Dan Dominic ;
Capalneanu, Radu ;
Brukner, Ioan ;
Dorobantu, Maria ;
Ambrosy, Andrew ;
Macarie, Cezar ;
Gheorghiade, Mihai .
AMERICAN HEART JOURNAL, 2011, 162 (01) :142-U189
[6]
An assessment of statin safety by hepatologists [J].
Cohen, DE ;
Anania, FA ;
Chalasani, N .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (8A) :77C-81C
[7]
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 [J].
Dickstein, Kenneth ;
Cohen-Solal, Alain ;
Filippatos, Gerasimos ;
McMurray, John J. V. ;
Ponikowski, Piotr ;
Poole-Wilson, Philip Alexander ;
Stromberg, Anna ;
van Veldhuisen, Dirk J. ;
Atar, Dan ;
Hoes, Arno W. ;
Keren, Andre ;
Mebazaa, Alexandre ;
Nieminen, Markku ;
Priori, Silvia Giuliana ;
Swedberg, Karl .
EUROPEAN HEART JOURNAL, 2008, 29 (19) :2388-2442
[8]
LIVER FUNCTION TESTS IN CHRONIC CONGESTIVE HEART FAILURE [J].
FELDER, L ;
MUND, A ;
PARKER, JG .
CIRCULATION, 1950, 2 (02) :286-297
[9]
Prevalence of hepatitis C in Romania: Different from European rates? [J].
Gheorghe, Liana ;
Lacob, Speranta ;
Csiki, Irma Eva .
JOURNAL OF HEPATOLOGY, 2008, 49 (04) :661-662
[10]
Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: Outcome Study with Tolvaptan (EVEREST) [J].
Gheorghiade, M ;
Orlandi, C ;
Burnett, JC ;
Demets, D ;
Grinfeld, L ;
Maggioni, A ;
Swedberg, K ;
Udelson, JE ;
Zannad, F ;
Zimmer, C ;
Konstam, MA .
JOURNAL OF CARDIAC FAILURE, 2005, 11 (04) :260-269